{"title":"评估慢性乙型肝炎患者肝脏硬度的无创检验:APRI、FIB-4 和 FIB-5 评分","authors":"Aysun Yakut, Murat Aladag","doi":"10.1155/2024/5540648","DOIUrl":null,"url":null,"abstract":"<div>\n <p><i>Background</i>. Invasive percutaneous liver parenchymal biopsy is the best test used to evaluate liver stiffness and fibrosis in the follow-up and treatment of chronic hepatitis B (CHB) patients. In this study, we aimed to indirectly evaluate the severity of liver parenchymal fibrosis with tests used in the laboratory. <i>Methods</i>. This retrospective study was conducted with 201 patients diagnosed with CHB who underwent liver biopsy between 2021 and 2022. Preprocedural examination information, laboratory tests, and histopathological data of the patients were taken from the hospital database and examined. “Aspartate aminotransferase (AST)-platelet ratio index” (APRI), “4 factor-based fibrosis index” (FIB-4) score, and “5 factor-based fibrosis index” (FIB-5) score were calculated and compared with liver histopathological features. <i>Results</i>. Of the 201 CHB patients, 76 were females and 125 were males. The average age of the patients was 38.05 ± 12.63 years. A weak, statistically significant correlation was observed between FIB-4 and APRI scores. The patients’ significant fibrosis scores were 31.3% and 33.8%, respectively (<i>r</i> = 0.313; <i>r</i> = 0.338; <i>p</i> = 0.001; <i>p</i> < 0.01). The very weak negative correlation of 17.4% between the patients’ FIB-5 score and fibrosis score was statistically significant (<i>r</i> = −0.174; <i>p</i> = 0.014; <i>p</i> < 0.05). <i>Conclusions</i>. According to the data we obtained in our study, while the APRI score and FIB-4 score can be used safely, more comprehensive studies are needed for the reliability of the FIB-5 score.</p>\n </div>","PeriodicalId":13782,"journal":{"name":"International Journal of Clinical Practice","volume":"2024 1","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/5540648","citationCount":"0","resultStr":"{\"title\":\"Noninvasive Tests to Assess Liver Stiffness in Patients with Chronic Hepatitis B: APRI, FIB-4, and FIB-5 Scores\",\"authors\":\"Aysun Yakut, Murat Aladag\",\"doi\":\"10.1155/2024/5540648\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n <p><i>Background</i>. Invasive percutaneous liver parenchymal biopsy is the best test used to evaluate liver stiffness and fibrosis in the follow-up and treatment of chronic hepatitis B (CHB) patients. In this study, we aimed to indirectly evaluate the severity of liver parenchymal fibrosis with tests used in the laboratory. <i>Methods</i>. This retrospective study was conducted with 201 patients diagnosed with CHB who underwent liver biopsy between 2021 and 2022. Preprocedural examination information, laboratory tests, and histopathological data of the patients were taken from the hospital database and examined. “Aspartate aminotransferase (AST)-platelet ratio index” (APRI), “4 factor-based fibrosis index” (FIB-4) score, and “5 factor-based fibrosis index” (FIB-5) score were calculated and compared with liver histopathological features. <i>Results</i>. Of the 201 CHB patients, 76 were females and 125 were males. The average age of the patients was 38.05 ± 12.63 years. A weak, statistically significant correlation was observed between FIB-4 and APRI scores. The patients’ significant fibrosis scores were 31.3% and 33.8%, respectively (<i>r</i> = 0.313; <i>r</i> = 0.338; <i>p</i> = 0.001; <i>p</i> < 0.01). The very weak negative correlation of 17.4% between the patients’ FIB-5 score and fibrosis score was statistically significant (<i>r</i> = −0.174; <i>p</i> = 0.014; <i>p</i> < 0.05). <i>Conclusions</i>. According to the data we obtained in our study, while the APRI score and FIB-4 score can be used safely, more comprehensive studies are needed for the reliability of the FIB-5 score.</p>\\n </div>\",\"PeriodicalId\":13782,\"journal\":{\"name\":\"International Journal of Clinical Practice\",\"volume\":\"2024 1\",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-07-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/5540648\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Clinical Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/2024/5540648\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/5540648","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
背景。在慢性乙型肝炎(CHB)患者的随访和治疗中,有创经皮肝实质活检是用于评估肝脏硬度和纤维化的最佳检测方法。在本研究中,我们的目的是通过实验室使用的检测方法间接评估肝实质纤维化的严重程度。研究方法这项回顾性研究的对象是 2021 年至 2022 年期间接受肝活检的 201 例确诊为慢性乙型肝炎的患者。患者的术前检查信息、实验室检测和组织病理学数据均来自医院数据库,并对其进行了检查。计算 "天冬氨酸氨基转移酶(AST)-血小板比值指数"(APRI)、"基于4因子的纤维化指数"(FIB-4)评分和 "基于5因子的纤维化指数"(FIB-5)评分,并与肝组织病理学特征进行比较。结果在 201 名慢性阻塞性肺病患者中,女性 76 人,男性 125 人。患者的平均年龄为(38.05 ± 12.63)岁。FIB-4 和 APRI 评分之间存在微弱的统计学相关性。患者的明显纤维化评分分别为 31.3% 和 33.8%(r = 0.313; r = 0.338; p = 0.001; p <0.01)。患者的 FIB-5 评分与纤维化评分之间存在极弱的负相关,为 17.4%,具有统计学意义(r = -0.174; p = 0.014; p <0.05)。结论根据我们的研究数据,虽然 APRI 评分和 FIB-4 评分可以安全使用,但 FIB-5 评分的可靠性还需要更全面的研究。
Noninvasive Tests to Assess Liver Stiffness in Patients with Chronic Hepatitis B: APRI, FIB-4, and FIB-5 Scores
Background. Invasive percutaneous liver parenchymal biopsy is the best test used to evaluate liver stiffness and fibrosis in the follow-up and treatment of chronic hepatitis B (CHB) patients. In this study, we aimed to indirectly evaluate the severity of liver parenchymal fibrosis with tests used in the laboratory. Methods. This retrospective study was conducted with 201 patients diagnosed with CHB who underwent liver biopsy between 2021 and 2022. Preprocedural examination information, laboratory tests, and histopathological data of the patients were taken from the hospital database and examined. “Aspartate aminotransferase (AST)-platelet ratio index” (APRI), “4 factor-based fibrosis index” (FIB-4) score, and “5 factor-based fibrosis index” (FIB-5) score were calculated and compared with liver histopathological features. Results. Of the 201 CHB patients, 76 were females and 125 were males. The average age of the patients was 38.05 ± 12.63 years. A weak, statistically significant correlation was observed between FIB-4 and APRI scores. The patients’ significant fibrosis scores were 31.3% and 33.8%, respectively (r = 0.313; r = 0.338; p = 0.001; p < 0.01). The very weak negative correlation of 17.4% between the patients’ FIB-5 score and fibrosis score was statistically significant (r = −0.174; p = 0.014; p < 0.05). Conclusions. According to the data we obtained in our study, while the APRI score and FIB-4 score can be used safely, more comprehensive studies are needed for the reliability of the FIB-5 score.
期刊介绍:
IJCP is a general medical journal. IJCP gives special priority to work that has international appeal.
IJCP publishes:
Editorials. IJCP Editorials are commissioned. [Peer reviewed at the editor''s discretion]
Perspectives. Most IJCP Perspectives are commissioned. Example. [Peer reviewed at the editor''s discretion]
Study design and interpretation. Example. [Always peer reviewed]
Original data from clinical investigations. In particular: Primary research papers from RCTs, observational studies, epidemiological studies; pre-specified sub-analyses; pooled analyses. [Always peer reviewed]
Meta-analyses. [Always peer reviewed]
Systematic reviews. From October 2009, special priority will be given to systematic reviews. [Always peer reviewed]
Non-systematic/narrative reviews. From October 2009, reviews that are not systematic will be considered only if they include a discrete Methods section that must explicitly describe the authors'' approach. Special priority will, however, be given to systematic reviews. [Always peer reviewed]
''How to…'' papers. Example. [Always peer reviewed]
Consensus statements. [Always peer reviewed] Short reports. [Always peer reviewed]
Letters. [Peer reviewed at the editor''s discretion]
International scope
IJCP publishes work from investigators globally. Around 30% of IJCP articles list an author from the UK. Around 30% of IJCP articles list an author from the USA or Canada. Around 45% of IJCP articles list an author from a European country that is not the UK. Around 15% of articles published in IJCP list an author from a country in the Asia-Pacific region.